Ohio’s health challenges demand thoughtful strategies to combat obesity

BALANCE Model could address an Ohio treatment gap

In 2023, 36.4% of Ohio adults reported obesity, representing approximately 3.4 million people. Obesity is a complex, chronic disease influenced by biological, behavioral, social, and environmental factors—not simply a lack of effort or character.

The Better Approaches to Lifestyle and Nutrition for Comprehensive Health, or BALANCE, Model is a voluntary federal demonstration for participating state Medicaid programs. It combines negotiated prices for selected FDA-approved medications with standardized coverage criteria and manufacturer-funded lifestyle support.

BALANCE Model could open access

Participating state Medicaid programs may obtain negotiated net prices through manufacturer supplemental rebates while covering selected medications for FDA-approved indications. Eligible adults must satisfy the model’s clinical criteria and any CMS-approved prior-authorization requirements.

Expanded legitimate coverage could give some patients an alternative to fraudulent or illegally marketed online products. However, BALANCE does not guarantee coverage, medical screening, or continuing clinical follow-up for every individual.

BALANCE includes lifestyle support

BALANCE is designed to combine selected medications with manufacturer-funded lifestyle support. Beneficiaries who receive a model drug for weight management through a participating Medicaid program are offered the support program at no additional cost.

The program is expected to address healthy eating, physical activity, medication adherence, and maintaining weight reduction. These services can complement medical treatment, but they do not replace individualized assessment, management of related conditions, or long-term clinical follow-up.

Ohio’s numbers demonstrate a substantial health burden

More than three million adults in Ohio live with obesity, showing how deeply the condition affects communities statewide. Without better access to care, the growing health burden can place more pressure on families, clinics, employers, and public programs each year.

Obesity raises the risk of type 2 diabetes, heart disease, stroke, and other serious conditions. Earlier, evidence-based treatment may prevent some complications, making a coordinated statewide strategy an important step toward protecting health and reducing long-term medical costs for Ohio.

Little-known fact: Obesity affects more than 2 in 5 U.S. adults, and in 2023, 23 states had adult obesity rates above 35%.

Online shortcuts can bring real risks

When insurance coverage is denied, some patients search online for cheaper obesity medicines or faster prescriptions. That search may lead to online sellers with unclear standards, limited follow-up, or products that have not been properly checked for quality and safety.

Safe treatment requires medical screening, correct dosing, side-effect monitoring, and coordination with other doctors. Ohio can protect patients by expanding legitimate access while setting stricter rules for online providers that operate without enough accountability, transparency, or reliable ongoing clinical support.

GLP-1 medicines changed the debate

GLP-1 receptor agonists have changed the way doctors and patients discuss obesity treatment. These medicines can support significant weight loss and may lower certain health risks for some people when they are prescribed correctly and monitored carefully by qualified professionals.

They are not quick cures, and they do not replace careful medical care. Providers must review health history, current medicines, goals, and possible side effects, making access to reliable clinical guidance just as important as access to the medication itself.

Little-known fact: The FDA approved Zepbound (tirzepatide) in 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related health condition.

Pediatric obesity care follows separate age-specific rules

Pediatric obesity care requires added caution because children and teens are still developing physically and emotionally. Ohio’s children’s hospitals can carefully evaluate young patients before considering GLP-1 medicines or other treatments, using specialists who understand complex childhood health needs well.

That review may include mental health, eating behaviors, family support, and related medical conditions. The goal is careful, age-appropriate care, with parents, specialists, and primary providers working together to protect each child’s health throughout treatment and follow-up visits over time.

Medicaid participation could close a coverage gap

ower-income Ohioans often face substantial barriers to obesity care, even when they have serious health risks. Expanded Medicaid coverage for FDA-approved obesity medicines could give eligible patients access to treatment through licensed professionals and established health systems across Ohio.

Supporters argue that obesity should be managed like other chronic diseases, including high blood pressure and asthma. Legitimate coverage could also reduce demand for unverified online products by giving patients a safer route to prescribed treatment and continuing medical support.

The cost debate needs a wider view

Some lawmakers focus on the upfront price of covering modern obesity medicines for many people. That concern matters, but it does not capture the full financial burden created when obesity-related diseases go untreated for years across communities and public programs.

Diabetes care, heart problems, strokes, hospital stays, and missed work can create major costs. Investing earlier in proven treatment may prevent some later expenses while improving daily life for patients who have often received little support for a chronic condition.

Other states illustrate different coverage approaches

Missouri uses prior-authorization criteria to determine Medicaid coverage for GLP-1 medicines, with eligibility depending on the drug, diagnosis, and clinical circumstances. Its policies demonstrate how states can limit coverage without excluding every FDA-approved use.

Louisiana initially covered Wegovy for qualifying Medicaid members with established cardiovascular disease. In June 2026, the state enacted a law creating a pathway for broader Medicaid coverage of medically necessary FDA-approved weight-loss medications beginning January 1, 2027, subject to funding and state coverage criteria.

Obesity treatment should remain coordinated

Obesity treatment works best when it stays linked to a patient’s regular health care. Primary care providers understand existing conditions, current prescriptions, family history, and health changes that can affect which treatment plan is safest and most effective over time.

When care is split between online sellers and local doctors, important details may be missed. Ohio can reduce that risk by supporting shared records and licensed providers who remain involved through every stage of treatment, starting with the first visit.

BALANCE’s application deadline has passed

State Medicaid agencies seeking ordinary participation were required to submit their applications by 11:59 p.m. EDT on July 31, 2026. Accepted states must execute a State Agreement with CMS and ordinarily begin participation no later than January 1, 2027.

As of August 2, Ohio’s application window has closed. Publicly available materials reviewed for this fact-check did not establish whether Ohio submitted an application. The slideshow should not say that state leaders still have until January 1 to apply.

Ohio’s property tax repeal campaign is racing against the clock to collect enough signatures. See what organizers must accomplish before the tight deadline arrives.

Coordinated policy could improve obesity care

Ohio’s obesity crisis will not be solved by online storefronts, shame, or one-size-fits-all advice. It requires safe medicines, trained providers, affordable coverage, strong oversight, and practical support that patients can use consistently as part of their daily lives each day.

Joining BALANCE and strengthening rules for risky online providers could move the state forward. The real challenge is building a system that expands access, protects safety, keeps doctors involved, and gives more Ohioans a fair chance at better health.

Ohio offers affordable living, strong communities, and plenty of attractions. Discover 14 reasons Americans are choosing to leave Ohio in 2026.

What do you think about expanding access to obesity treatments in Ohio? Share your thoughts in the comments.

This slideshow was made with AI assistance and human editing.

Read More From This Brand:

• Ohio Medicaid home healthcare limits stall after care access concerns
• Ohio sees new voter outreach campaign after federal raid on office
• Supreme Court ruling could have major implications for Haitians in Ohio